CERVICAL DYSTONIA is a painful and disabling chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck. 

BOTULINUM TOXIN (BNT) injections are the current standard of care. 

ON THE PATIENTS’ DAILY LIFE IS MEASURED BY SEVERITY, PAIN, AND DISABILITY and is commonly used in the evaluation and treatment of cervical dystonia.

DaxibotulinumtoxinA for Injection is a randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia. 

**ASPEN 1**

**301 SUBJECTS**

**3:3:1 randomization**

**ASPEN STUDY SITES** United States, Canada, and Europe

**MEASURE OF EFFICACY**

- **TWSTRS** was used to assess each patient’s severity, pain and disability caused by cervical dystonia over time.

**BASELINE** Average of weeks 4 and 6

**TREATED WITH:**

- **PRIMARY ENDPOINT**
  - WITH MODERATE TO SEVERE CERVICAL DYSTONIA: The average of the change from baseline at weeks 4 and 6 in TWSTRS Total Score.
  - Duration of Effect, as defined as time from treatment to loss of 80% of the peak treatment effect achieved at weeks 4 and 6.

**SECONDARY ENDPOINT**

- For toxin naïve and experienced

**p<0.0001** (125 U vs. Placebo) 

**p=0.0006** (250 U vs. Placebo) 

**p=0.1902** (250 U vs. 125 U) 

* LSM=Least Square Means.

**∆ Change FROM Baseline OVERALL IMPACT OF CERVICAL DYSTONIA Patients were followed for up to 36 WEEKS.**

**REFERENCES**


**DaxibotulinumtoxinA for Injection is an investigational agent that is not yet approved by the FDA.**

**Phase 3 Study for the Treatment of Cervical Spasm**

The study results suggest that DaxibotulinumtoxinA for Injection has the potential to REDUCE FREQUENCY OF CERVICAL DYSTONIA TREATMENTS by up to 50% ANNUALLY. 

**RESIDUAL DURATION OF RESPONSE AT 24 WEEKS with 250 U dose of DaxibotulinumtoxinA for Injection.**